AmpliPhi Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch APHB and buy or sell other stocks, ETFs, and their options commission-free!

About APHB

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA. 

CEO
Deborah L. Birx, MD
CEODeborah L. Birx, MD
Employees
Employees
Headquarters
Los Angeles, California
HeadquartersLos Angeles, California
Founded
1989
Founded1989
Employees
Employees

APHB Key Statistics

Market cap
422.68M
Market cap422.68M
Price-Earnings ratio
-8.78
Price-Earnings ratio-8.78
Dividend yield
Dividend yield
Average volume
54.15K
Average volume54.15K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$16.34
52 Week high$16.34
52 Week low
$0.8981
52 Week low$0.8981

Stock Snapshot

As of today, AmpliPhi Biosciences(APHB) shares are valued at $3.51. The company's market cap stands at 422.68M, with a P/E ratio of -8.78.

During the trading day, AmpliPhi Biosciences(APHB) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 54.15K.

The stock's 52-week range extends from a low of $0.90 to a high of $16.34.

The stock's 52-week range extends from a low of $0.90 to a high of $16.34.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.